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ttp://dx.doi.org/10.1016/j.ajpath.2014.08.021Evidence linking prostatitis and prostate cancer development is contradictory. To study this link, the
POET3 mouse, an inducible model of prostatitis, was crossed with a Pten-loss model of prostate cancer
(Ptenþ/) containing the ROSA26 luciferase allele to monitor prostate size. Prostatitis was induced, and
prostate bioluminescence was tracked over 12 months, with lesion development, inﬂammation, and
cytokine expression analyzed at 4, 8, and 12 months and compared with mice without induction of
prostatitis. Acute prostatitis led to more proliferative epithelium and enhanced bioluminescence.
However, 4 months after initiation of prostatitis, mice with induced inﬂammation had lower grade pre-
neoplastic lesions. A trend existed toward greater development of carcinoma 12months after induction of
inﬂammation, including one of two mice with carcinoma developing perineural invasion. Two of 18 mice
at the later time points developed lesions with similarities to proliferative inﬂammatory atrophy,
including one mouse with associated carcinoma. Ptenþ/mice developed spontaneous inﬂammation, and
prostatitis was similar among groups of mice at 8 and 12 months. Analyzed as one cohort, lesion number
and grade were positively correlated with prostatitis. Speciﬁcally, amounts of CD11bþGr1þ cells were
correlated with lesion development. These results support the hypothesis that myeloid-based inﬂam-
mation is associated with lesion development in the murine prostate, and previous bouts of CD8-driven
prostatitis may promote invasion in the Ptenþ/ model of cancer. (Am J Pathol 2014, 184: 3176e3191;
http://dx.doi.org/10.1016/j.ajpath.2014.08.021)Supported by NIH grants R01 DK84454 (T.L.R.), R21 CA154126
(M.D.H. and T.L.R.), and 5T32OD011122 (salary support for G.N.B.) and
Purdue University Center for Cancer Research grant P30 CA023168
(T.L.R.).
Disclosures: None declared.The importance of the immune system and chronic inﬂam-
mation in the pathogenesis of cancer development has been
recognized by recent inclusion of inﬂammation as an enabling
characteristic of cancer formation.1 Inﬂammation has been
shown to promote tumor formation in multiple tissues, with
some of the most notable examples in the gastrointestinal tract,
including reﬂux esophagitis and esophageal cancer,
Helicobacter-associated gastritis and gastric cancer, and in-
ﬂammatory bowel disease and colorectal cancer.2e4
Both prostate cancer and prostatitis are common diseases in
American men; prostate cancer is the most common malig-
nancy in American men, and the prevalence of prostatitis is as
high as 9% by age 79 years according to one Minnesota-based
study.5 Given the high prevalence of both diseases and thestigative Pathology.
.association between chronic inﬂammation and cancer, a causal
relation between the two diseases seems plausible. However,
current epidemiologic and clinical evidence about the relation
between inﬂammation and carcinogenesis in the prostate is
contradictory.
Within the past year, a meta-analysis including 20 rela-
tively recent case-control and cohort studies examining the
link between prostatitis and prostate cancer found a positive
Lesion Development in POET3þ Ptenþ/ Miceassociation between the presence of inﬂammation and
prostate cancer development.6 In addition in 2013, a study
of prostatitis and benign prostatic hyperplasia found a
relevant association between prostatitis and prostate cancer
and between benign prostatic hyperplasia and cancer
development in Asian men, a population with lower overall
incidence of prostate cancer.7 Concurrently, two biopsy-
based studies were published that identiﬁed and scored
both acute and chronic inﬂammation in prostatic biopsies
that were negative for carcinoma on initial screening. Both
studies, one performed in Finland, the other in the United
States, found that the presence of acute or chronic inﬂam-
mation on the initial biopsy was negatively associated with
development of prostate cancer in follow-up biopsies.8,9
Interestingly, in both studies the presence of acute prosta-
titis on the initial screening resulted in a lower cumulative
risk for development of prostate cancer in subsequent
screenings.
Many epidemiologic studies about anti-inﬂammatory
treatment and prostate cancer risk have also been conducted,
with similarly conﬂicting results. In several studies, taking
aspirin is associated with decreased prostate cancer risk,
whereas other nonsteroidal anti-inﬂammatories either in-
crease prostate cancer risk or have no effect.10,11 Other
studies show that aspirin treatment has no protective effect on
prostate cancer development, and other nonsteroidal anti-
inﬂammatories have only a modest effect.12 History of
sexually transmitted disease has also been variably associated
with prostate cancer development. In results from a recent
prospective study of men’s health in California, the presence
of prostatitis was positively associated with prostate cancer
development, but previous infection with a sexually trans-
mitted disease increased the risk of prostate cancer devel-
opment only in certain ethnic groups, a ﬁnding at odds with
previous studies of sexually transmitted diseases and prostate
cancer risk.13 Taken together, the published epidemiologic
and clinical data linking prostatitis and cancer development
are mixed, with strong recent evidence to suggest that the
presence of histologically conﬁrmed prostatitis is protective
for prostate cancer development.
Other approaches have also been used to examine this
potential link, including in vitro studies using prostate cancer
cell lines and treatment with inﬂammatory cytokines and
in vivo studies using animal models. As one example of the
in vitro evidence linking prostatitis and cancer development,
studies examining the effects of IL-6 on prostate cancer cell
line growth confer a growth advantage and enhanced
vascular endothelial growth factor production to chronically
treated LNCaP cells.14,15 Animal models of prostatitis have
been developed, with a few used to investigate in-
ﬂammation’s effect on carcinogenesis in vivo. With the use of
uropathogenic Escherichia coli infection of the prostate as a
model of prostate inﬂammation, previously infected murine
prostates showed enhanced hyperplasia and dysplasia with
higher degrees of oxidative damage to epithelial cell DNA,
suggesting inﬂammation can lead to the early steps of cellularThe American Journal of Pathology - ajp.amjpathol.orgtransformation.16 In another mouse model, inhibitor of NF-
kB (IkB) kinase 2 was constitutively activated in the prostate
of mice with prostate-speciﬁc deletion of the tumor sup-
pressor Pten. IkB kinase 2 activation mimics chronic
inﬂammation through downstream activation of NF-kB, a
master transcription factor for several proinﬂammatory
pathways. Here, mice with both activation of IkB kinase 2
and loss of one allele of Pten had larger epithelial lesions and
increased ﬁbrous stroma in the prostate compared with mice
with loss of Pten only but no development of invasive
lesions.17 Thus, pieces of in vitro and in vivo evidence sug-
gest a positive association between inﬂammation and pros-
tate carcinogenesis.
We are interested in investigating the effects of prostatitis
on prostate cancer development in an animal model relevant
to both diseases. Prostatitis is currently classiﬁed as acute
bacterial, chronic bacterial, asymptomatic inﬂammatory, or
chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS),
which can be either inﬂammatory or noninﬂammatory.18
Approximately 90% of all cases of prostatitis are diagnosed
as CP/CPPS, which has evidence for an autoimmune
component as part of the syndrome’s complex pathogen-
esis.19 Because many cases of prostatitis may have an auto-
immune component, the POET-3 mouse model of prostatitis
was developed and previously characterized by our labora-
tory.20 This model makes use of the availability of tools
already in place by using ovalbumin as a prostate-speciﬁc
model antigen. Prostatitis is induced in a controlled manner
via adoptive transfer of preactivated CD8þ OT-I T cells,
which bear a transgenic T-cell receptor recognizing a peptide
in the ovalbumin protein. Acute prostatitis is followed by a
chronic phase, with detection of enhanced concentrations of
leukocytes up to 80 days after induction of inﬂammation.20
This model was crossed with the C57/Luc/Ptenþ/ mouse
model of prostate carcinogenesis, which uses the Cre-loxP
system driven by the prostate-speciﬁc Probasin promoter to
inactivate one allele of Pten in the prostate.21 The prostate-
speciﬁc expression of luciferase allows for in vivo imaging
of the prostate over time.
Using this model, two episodes of prostate-speciﬁc
inﬂammation were induced to study the effects of inﬂam-
mation in a model that develops subtle epithelial lesions over
several months. The studies addressed the hypothesis that
induced prostatitis would enhance the development of pre-
cancerous epithelial lesions. In the acute phase, prostate
epithelium was highly proliferative and showed enhanced
bioluminescence. However, by 4 months after inﬂammation,
mice with previous bouts of inﬂammation showed similar
numbers of lesions and slightly decreased average grade of
lesions compared with those mice in which inﬂammation was
not induced, although spontaneous inﬂammation was
observed in noninduced mice. A trend toward invasion was
observed at later time points in mice with induced inﬂam-
mation, but average lesion grade, size of lesions, and number
of lesions were unchanged between the induced and non-
induced mice. Taking into consideration that Ptenþ/ mice3177
Burcham et aldevelop spontaneous prostatitis over time, the mice were also
analyzed as a single cohort, and a positive association be-
tween myeloid cell inﬁltration and lesion development was
observed.
Materials and Methods
Mice and Genotyping
Animal experiments described in this study were approved
by the Purdue University Animal Care and Use Committee.
The C57/Luc/Pten/ mouse model resulted from inter-
breeding PB-Cre4þmice [B6.Cg-Tg(Pbsn-cre)4Prb], Ptenﬂ/ﬂ
mice (C;129S4-Ptentm1Hwu/J), and ROSA26-LSL-Luc mice
[FVB.129S6 (B6)-Gt (ROSA)26Sortm1(Luc)Kael/J], and back-
crossing the resulting mice with albino C57BL/6 mice
(C57BL/6J-Tyrc-2J/J), as previously described.21 These
mice were interbred with POET-3 mice, a previously
described model of prostatitis, to obtain P3þPten/ mice
containing the POET-3 transgene; PB Cre, ﬂoxed alleles of
Pten; and prostate luciferase expression.20 Genotypes needed
for this study were generated via the speed expansion service
at The Jackson Laboratory (Bar Harbor, ME), where sperm
from C57/Luc/Pten/ and C57/Luc/Ptenþ/ mice also
hemizygous for the POET-3 transgene were used to fertilize
ova from albino C57BL/6 mice (C57BL/6J-Tyrc-2J/J). The
resulting mice were either hemizygous (P3þ) or negative
(P3) for the POET-3 transgene, had two intact Pten alleles
(Ptenþ/þ) or one allele of Pten ﬂoxed (Ptenþ/), were
hemizygous for PB-Cre (PB-Creþ), and were hemizygous for
ROSA26-LSL-Luc (Lucþ). Mice were genotyped for the
presence of all genetic mutations, as previously described.21
In Vivo Bioluminescence Imaging
Mice for in vivo imaging were anesthetized with a combi-
nation of ketamine and xylazine and were dosed intraperi-
toneally with 0.15 mg/g of body weight D-Luciferin ﬁreﬂy
potassium salt (Gold Biotechnology, St. Louis, MO) dis-
solved in Dulbecco’s phosphate-buffered saline. Mice were
placed in dorsal recumbency, and bioluminescent signal was
imaged with the IVIS Lumina II (Caliper Life Sciences,
Hopkinton, MA). Bioluminescence was collected by using a
2-minute exposure at 5-minute intervals for up to 30 minutes.
Bioluminescence was measured in photons ﬂux/second
within a region of interest, deﬁned as 8%maximum signal by
using the Living Image software version 4.0 (Caliper Life
Sciences). The single, peak bioluminescent signal obtained
over the 30-minute imaging session for each mouse was used
in data analysis.
Induction of Prostatitis
Splenocytes were isolated from male Rag1/ OT-I mice [a
cross between B6.129S7-Rag1tm1Mom/J mice obtained from
The Jackson Laboratory and Tg(TcraTcrb) 1100Mjb mice3178obtained as a gift from Dr. William Heath (Walter and Eliza
Hall Institute, Melbourne, Australia)] and cultured at 5 105/
mLwith 1 mg/mL SIINFEKL (ova peptide 357-264; American
Peptide Company Inc., Sunnyvale, CA) for 48 hours in RPMI
1640 medium with 10% fetal bovine serum, 5% sodium py-
ruvate, 5% penicillin-streptomycin, and 5% 1 mol/L HEPES.
Live cells were puriﬁed by Fico/Lite (Atlanta Biologicals,
Norcross, GA), and 5 106 cells were injected intravenously.
Flow Cytometry
Single-cell suspensions of prostates were obtained by
mincing the tissues in a solution of RPMI 1640 medium with
2 mg/mL collagenase D (Roche Diagnostics, Indianapolis,
IN) and digesting the tissue at 37C for approximately 1 hour.
Single-cell suspensions of splenocytes were also collected
from each mouse. Cells were ﬁltered via 35-mm mesh cell
strainer caps, washed with medium, and treated with TruSt-
ain fcX anti-CD16/32 antibody (catalog 101319; BioLegend,
San Diego, CA), then labeled with the following directly
conjugated anti-mouse antibodies according to the manu-
facturer’s instructions: BioLegend peridinin chlorophyll anti-
CD45 (catalog 103129), ﬂuorescein isothiocyanate (FITC)
anti-CD45 (catalog 103107), phosphatidylethanolamine
(PE)/cyanine 7 anti-CD45R/B220 (catalog 103221), FITC
anti-CD4 (catalog 100405), PE anti-CD11b (catalog
101207), PE/cyanine 7 anti-CD11b (catalog 101215), allo-
phycocyanin antieGr-1 (catalog 108411), FITC anti-F4/80
(catalog 123107), PE anti-FcεRIa (catalog 134307), and
allophycocyanin anti-CD4 (catalog 17-0042-81;eBioscience,
San Diego, CA). Aliquots of sample were separated and
labeled with the appropriate isotype control antibodies
(BioLegend). Labeling for the intracellular antigen FOXP3
was performed with the PE-conjugated anti-FOXP3 Flow Kit
(BioLegend). Analysis was performed with the FACSCanto
II (BD Biosciences, San Jose, CA), and data were further
analyzed with FlowJo software version 9 (TreeStar Inc.,
Ashland, OR).
RNA Isolation, cDNA Synthesis, and RT-PCR
Sections of each lobe of the prostate were ﬂash frozen in liquid
nitrogen and stored at 80C before homogenization. For
RNA extraction, tissues were submerged in 2 mL of TRK lysis
buffer (Omega Bio-Tek Inc., Norcross, GA) and homogenized
with the Tissue Tearor (BioSpec Products, Inc., Bartlesville,
OK). Lysates were centrifuged, and the supernatant was
collected. RNAwas isolated from the supernatant by using the
Total RNA isolation kit I (Omega Bio-Tek Inc.), and cDNA
synthesis was performed with qScript cDNA SuperMix
(Quanta BioSciences, Inc., Gaithersburg, MD). RT-PCR was
performed with LightCycler 96 Real-Time PCR System
(Roche Diagnostics) and PrimeTime qPCR probes (Integrated
DNA Technologies, Inc., Coralville, IA) for the following
genes: Il1b (assay, Mm.PT.56a.41616450), Il2 (assay,
Mm.PT.56a.11478202), Il4 (assay, Mm.PT.56a.32703659),ajp.amjpathol.org - The American Journal of Pathology
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6a.10005566), Il10 (assay, Mm.PT.56a.13531087), Il13
(assay, Mm.PT.56a.31366752), and Il6ra (assay, Mm.PT.58.
31166746). TaqMan qPCR probes were used to detect the
following genes: Ifng (assay, Mm00801778_m1), Tnf (assay,
Mm00443258_m1), and Tgfb1 (assay, MM00441724_m1).
As an endogenous control the 18s rRNA gene was detected
via TaqMan Ribosomal RNA Control reagents (catalog
4308329; Applied Biosystems, Foster City, CA) and used for
normalization. Relative amounts of mRNA were calculated
as 2(Ct gene of interestCt 18s rRNA), where Ct is the threshold
cycle value.
Histology and Digital Slide Analysis
Prostate tissue was ﬁxed with 10% neutral-buffered formalin
for 24 to 48 hours, followed by routine tissue processing and
parafﬁn embedding. A representative 5-mm section of each of
the four lobes was obtained and stained with hematoxylin and
eosin (H&E). Slides were digitized with an Aperio Digital
Slide Scanner (Leica, Wetzler, Germany), and slides were
analyzed by two board-certiﬁed veterinary pathologists
(G.N.B. and P.W.S.) and annotated with ImageScope soft-
ware version 11.2.0.780 (Leica). Individual mouse prostatic
intraepithelial neoplasia (mPIN) and carcinoma lesions were
outlined and measured with the ImageScope software.
Immunohistochemical analysis was performed by using
either the nuclear version 9 or the membrane version 9 al-
gorithms, depending on the localization of the labeling.
Average lesion grade was obtained by calculating as follows:
½ðNumber PIN I lesions 1Þ þ ðNumber of PIN II lesions 2Þ
þ ðNumber of PIN III leisons 3Þ
þ ðNumber of carcinoma lesions 4Þ=Total number of lesions:
ð1Þ
A grading scheme modiﬁed from previously published
schemes was developed and used to separate mPIN lesions
into three separate grades (PIN I, II, III); criteria for carcinoma
were adapted from the Bar Harbor meeting of the Mouse
Models of Human Cancer Consortium Prostate Pathology
Committee.22e24 A three-tier grading scheme for histologic
presence of prostatic inﬂammation was modiﬁed from an
existing grading scheme; each lobe was scored individually,
and a sum of the scores was used as the total prostate
inﬂammation.25
Immunohistochemistry
For antieKi-67 and antieBcl-2, tissue sections were depar-
afﬁnized, rehydrated, submerged in decloaker solution (Bio-
care Medical, Concord, CA), and heated to 96C for 20
minutes by using a laboratory microwave (Ted Pella, Inc.,
Redding, CA). Sections were then treated with 3% hydrogen
peroxide, protein block solution (Dako, Carpinteria, CA),
primary antibody (antieKi-67 sp6 clone, antieBcl-2 E17The American Journal of Pathology - ajp.amjpathol.orgclone; Abcam Inc., Cambridge, MA), peroxidase-linked
polymeric anti-rabbit antibody (Dako), and ﬁnally 3,30-dia-
minbenzidine substrate; washes with tris-buffered saline that
contained 0.5% Tween 20 were conducted between each step.
Slides were counterstained with hematoxylin. For antie
p-AKT, tissue sections were deparafﬁnized, rehydrated, sub-
merged in antigen unmasking solution (Vector Laboratories,
Burlingame, CA), heated to 121C in a benchtop autoclave
(2100-Retriever; Prestige Medical, Northridge, CA), and
allowed to cool to room temperature. Sections were pretreated
with 3% H2O2, then incubated with primary antibody (antie
p-AKT serine 473; Cell Signaling Technology Inc., Danvers,
MA) and anti-rabbit secondary antibody (BA-1000; Vector
Laboratories). Sections were incubated with Vectastain Elite
ABC reagent (Vector Laboratories) and peroxidase substrate
solution (Vector Laboratories), followed by hematoxylin
counterstain. Appropriate target-speciﬁc positive and negative
control tissues were used.
Cell Sorting
A previously published protocol for isolation of prostate
epithelia was followed.26 Brieﬂy, minced prostate tissue was
digested with 1 mg/mL collagenase-I in RPMI 1640 medium
containing 10% fetal bovine serum for 2 hours, after trypsi-
nization at 37C to isolate cells. The suspensions were passed
through 20-gauge needles three to ﬁve times and 40-mm cell
strainers. To enrich prostate epithelial cells, isolated cells were
incubated with ﬂuorescence-conjugated speciﬁc antibodies as
follows: Sca1-allophycocyanin (catalog 108112; BioLegend),
CD49f-PE (catalog 12-0495-83; eBioscience), CD45-FITC
(catalog 103108; BioLegend), and CD31-FITC (catalog
553372; BD Biosciences).27 CD45CD31Sca1þCD49fþ
(prostate progenitors), CD45CD31Sca1CD49f (luminal
cells), and CD45CD31Sca1CD49fþ (basal cells) were
collected via live cell sorting with the use of a FACSAria (BD
Biosciences).
Western Blot Analysis
Cell lysates were prepared by addition of RIPA lysis buffer
(Rockland Immunochemicals, Inc., Gilbertsville, PA)
containing 1 protease inhibitor cocktail (catalog P8340;
Sigma-Aldrich, St. Louis, MO), 1 PhosphataseArrest I
(G-Biosciences, St. Louis, MO), 1 mmol/L phenyl-
methylsulfonyl ﬂuoride, and 0.1% Triton X-100. Protein
concentrations were determined with Bradford reagent
(catalog B6916; Sigma-Aldrich) according to the manufac-
turer’s instructions by using dilutions of 2 mg/mL bovine
serum albumin (Thermo Scientiﬁc, Waltham, MA) to pro-
duce a standard curve for each experiment. Approximately
30 to 40 mg of protein per sample was loaded into wells
for electrophoresis. Western blot analyses were performed
by probing polyvinylidene diﬂuoride membranes with
the following antibodies: antieb-actin clone 8H10D10,
antiephospho-IkB (14D4) rabbit monoclonal antibody3179
Burcham et al2859, and antiephospho-IkB (44D4) rabbit monoclonal
antibody 4812 (Cell Signaling Technology Inc.).
Statistical Analysis
Statistical analyses were performed with Prism version 5.04
(GraphPad Inc., La Jolla, CA). Student’s t-test and analysis of
variance were used in cases of data with expected normal
distribution, with Mann-Whitney test used in cases of non-
normal distribution. Correlations between sets of contin-
uous data were analyzed by ﬁtting simple linear regression.
Statistical signiﬁcance was considered with P < 0.05.
Results
Bioluminescence and Cell Proliferation Increase during
the Acute Phase of Prostatitis
To study prostatitis and its potential effects on prostate cancer
formation, a previously described model of inducible CD8þ
T-celledriven prostatitis, the POET-3 mouse,20,28 was crossed
with a prostate-speciﬁcPten-deﬁcient model of prostate cancer
formation that included the ROSA26 luciferase allele to allow
in vivomonitoring of prostate size21 (Figure 1A). Both mouse
models were previously backcrossed onto the C57Bl/6 back-
ground to ensure genetic homogeneity. Once the POET-
3/C57/Luc/Pten/mice were available, adequate numbers of
mice for experimentation were generated with The Jackson
Laboratory’s speed expansion service. Speed expansion
generated four genotypes for study: POET-3þ/C57/Luc/
Ptenþ/ (designated P3þPtenþ/), POET-3/C57/Luc/Ptenþ/
(designated P3Ptenþ/), POET-3þ/C57/Luc/Ptenþ/þ
(designated P3þPtenþ/þ), and POET-3/C57/Luc/Ptenþ/þ
(designated P3Ptenþ/þ). Thus, mice were generated with
the ability to form epithelial lesions (Ptenþ/) and with and
without the transgene that allows inducible inﬂammation
(POET-3). For comparison, mice with intact Ptenþ/þ with
and without the POET-3 transgene were also generated.
At 12 weeks of age, all genotypes of mice had similar
amounts of bioluminescence, which increased gradually over
time (Figure 1, C and D). At weeks 13 and 18 all mice received
activated OT-I cells via adoptive transfer (Figure 1B). Prosta-
titis was induced only in POET-3þ mice as previously
described.20 Groups of 10 mice (5 P3þPtenþ/, 5 P3Ptenþ/)
or 8 mice (4 P3þPtenþ/þ and 4 P3Ptenþ/þ) were euthanized
and evaluated at 4, 8, and 12 months after induction of pros-
tatitis (Figure 1B). Bioluminescent imaging was performed
every 1 to 2 weeks during the study. P3þPtenþ/þ mice with
induced prostatitis had signiﬁcantly increased (P < 0.001)
bioluminescence in the 2 weeks after each instance of adoptive
transfer of OT-I T cells; however, bioluminescence normalized
soon after each episode and remained similar in each group for
the remainder of the study (Figure 1C). In contrast, P3þPtenþ/
mice had signiﬁcantly increased bioluminescence (P < 0.001)
immediately after the ﬁrst adoptive transfer of OT-I T cells at
13 weeks, which persisted until the second adoptive transfer of3180T cells at 18 weeks (Figure 1D). Interestingly, the second
episode of prostatitis resulted in a greater increase in biolumi-
nescence compared with the ﬁrst, suggesting enhanced
epithelial cell proliferation after repeated episodes of inﬂam-
mation (Figure 1D). Prostatitis was veriﬁed via histopathology,
which showed diffuse interstitial inﬁltration of lymphocytes,
with fewer numbers of macrophages and neutrophils
throughout prostates of P3þPtenþ/mice after adoptive transfer
of OT-I T cells, with no detectable inﬂammation in P3þPtenþ/
mice before adoptive transfer and P3Ptenþ/ mice after
adoptive transfer (Figure 2A). Immunohistochemical labeling
for Ki-67 showed a signiﬁcant increase in epithelial cell pro-
liferation in all lobes of the prostates of P3þPtenþ/ mice
(P < 0.0001) compared with both P3þPtenþ/ mice before
adoptive transfer of OT-I T cells and P3Ptenþ/ also chal-
lenged with OT-I T cells (Figure 2B). Approximately 50% of
prostate epithelial cells labeled positively with Ki-67 in
P3þPtenþ/ mice after induction of inﬂammation, suggesting
CD8þ T-celledriven prostatitis was a strong signal for
epithelial cell proliferation. Immunohistochemical labeling of
phosphorylated Akt (p-Akt) was used as an indicator of lesion
development in these mice, as previously described, and areas
of p-Aktþ epithelium were increased (P < 0.01) in the lateral
lobes ofmice during the acute phase of prostatitis (Figure 2C).21
Some differences were observed in cell proliferation, with
decreased proliferation in the ventral lobe, and Akt labeling,
with increased labeling in the lateral lobe. Differences were
likely not due to the amount of inﬂammation, because all lobes
were shown to have similar inﬂammatory inﬁltrate in this
model.20 Differences could be a result of an as yet undescribed
difference in epithelial cell biology between different prostate
lobes in the mouse. Taken together, the above results indicated
that severe prostatitis in P3þPtenþ/ mice lead to epithelial cell
hyperplasia in the acute phase of inﬂammation and initial early
expansion of multifocal areas of epithelium.
Experimentally Induced Prostatitis Does Not Translate
into Increased Incidence, Size, or Grade of Epithelial
Precursor Lesions
To test our hypothesis that induced inﬂammation promotes
enhanced carcinogenesis in an environment permissive to cell
proliferation, ﬁve P3þPtenþ/ and ﬁve P3Ptenþ/ mice were
sacriﬁced at 4, 8, and 12months after induction of prostatitis. At
each time point, prostate tissue was collected and examined
histologically. A grading scheme modiﬁed from previously
published schemes was developed and used to separate mPIN
lesions into the following three separate grades: PIN I, II, and
III, with PIN III being the most severe of the precursor lesions
observed.22,23 Biological differences in the grading scheme
were validated via immunohistochemical labeling for Ki-67, in
which the proliferative index was increased with higher grades
(see PIA-Like Lesions Are Present in Areas of Inﬂammation
and Fibrosis). Lesions were counted, graded, and measured
in each lobe. As expected from previously published data that
used the C57/Luc/Ptenþ/, lesion development was slow, withajp.amjpathol.org - The American Journal of Pathology
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age) and only rare instances of carcinoma developing in the 12-
month group (60weeks of age) (Figure 3A).21 At 4months after
induction of prostatitis, the incidence of epithelial lesions did
not differ between P3þPtenþ/ and P3Ptenþ/ mice
(Figure 3B), and the average grade of mPIN lesions was lower
in P3þPtenþ/mice (PZ 0.02), suggesting that prostatitis may
have inﬂuenced or slowed lesion development in these mice
(Figure 3C). By 8 and 12 months after inﬂammation, incidence
of epithelial lesions and average grade of lesions were statisti-
cally similar in both groups of mice (Figure 3, B and C).
Similarly, the size of PIN I and PIN II lesions did not differ
between the two groups of mice at 4, 8, or 12 months after
inﬂammation (Figure 3D and data not shown). No differences
were detected between the sizes of PIN III lesions, although
there were small total numbers of PIN III lesions and large
variation between PIN III sizes (data not shown).
In contrast to mice with loss of one allele of Pten, only rare
instances of epithelial lesions were observed the P3þPtenþ/þFigure 1 Bioluminescence increased with induction of prostatitis. A: A schema
C57/Luc/Pten/ model of prostate carcinogenesis that contains Cre recombinase
the prostate; and prostate-speciﬁc inactivation of Pten was crossed with the POE
Experimental timeline shows ages of treatments and timing of tissue harvests. C: B
prostatitis. D: Bioluminescence increased in the weeks after induction of prostatit
12 to 14 early time points (C); nZ 4 later time points (C); nZ 15 to 22 early tim
and ****P < 0.0001, Student’s t-test.
The American Journal of Pathology - ajp.amjpathol.organdP3Ptenþ/þmice (Supplemental Figure S1A).However, an
interesting trend toward the presence of hyperplastic lesionswas
observed in the P3þPtenþ/þ mice, with one of three P3þ mice
developing at least one instance of hyperplasia at 4 months after
inﬂammation and no mice developing lesions in the P3 group
at 4 months (data not shown). Hyperplastic lesions were
observed in a single P3þPtenþ/þ mouse at 8 months after
inﬂammation, but lesions were not observed in the P3Ptenþ/þ
mouse group (data not shown). By 12 months after induction of
inﬂammation, threemice in theP3Ptenþ/þ grouphad instances
of hyperplasia, with no hyperplasia observed in P3þPtenþ/þ
mice; however, at least one instance of PIN I was seen in the
previously inﬂamed mice (Supplemental Figure S1A).
Experimentally Induced Prostatitis May Promote
Development of Invasive Lesions
Although experimental induction of prostatitis did not result
in an increased incidence or higher grade of epithelialtic shows the two major mouse models that were crossed for this study: the
driven by the prostate-speciﬁc promoter probasin, luciferase expression in
T-3 model, allowing for controlled induction of autoimmune prostatitis. B:
ioluminescence of P3þPtenþ/þ mice increased transiently after induction of
is in P3þPtenþ/ mice. Data are expressed as means  SEM (C and D). nZ
e points (D); nZ 4 to 5 later time points (D). **P < 0.01, ***P < 0.001,
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Figure 2 Prostatitis increased the percentage of dividing epithelial cells and number of cells with enhanced Akt signaling. A: P3þPtenþ/ before adoptive
transfer of OT-I T cells at 12 weeks of age and P3Ptenþ/ mice after adoptive transfer of OT-I T cells at 13 weeks of age showed no prostatitis by H&E staining,
low amounts of cell proliferation by antieKi-67 IHC, and few cells with enhanced phosphorylation of Akt by antiep-Akt IHC. P3þPtenþ/ mice 6 days after
adoptive transfer of OT-I T cells at 13 weeks of age showed severe prostatitis by H&E staining, high amounts of cell proliferation by antieKi-67 IHC, and larger
areas of cells with enhanced phosphorylation of Akt by antiep-Akt IHC. Anterior lobes shown in H&E, Ki-67 panels; lateral lobes shown in p-Akt panels. B:
Quantiﬁcation of antieKi-67 IHC in the three groups of mice represented in A. C: Quantiﬁcation of antiep-Akt IHC in the three groups of mice represented in
A. Data are expressed as means  SEM (B and C). n Z 5 mice each group (B); n Z 5 mice in Pre and P3 (C); n Z 4 mice in P3þ (C). **P < 0.01,
****P < 0.0001, one-way analysis of variance or Student’s t-test. IHC, immunohistochemistry.
Burcham et allesions as hypothesized, several noteworthy histologic obser-
vations were made in P3þPtenþ/ prostates. First, a trend to-
ward increased carcinoma development was present in
P3þPtenþ/ mice compared with P3Ptenþ/ mice. Carci-
noma was observed only in the mice evaluated at 12 months
after prostatitis induction, with two of ﬁve P3þPtenþ/ mice
and one of ﬁve P3Ptenþ/ mice developing carcinoma
(Figure 3E). In one P3þPtenþ/ mouse with carcinoma, the
mouse was removed from the study 2 months earlier than
scheduled because of acute onset of lethargy and inappetence.
Grossly the prostate was enlarged, and the urinary bladder was
swollen, with multiple areas of serosal hemorrhage
(Figure 4A). Microscopically there were multiple mPIN le-
sions throughout the prostate and periprostatic suppurative
inﬂammation. Within the wall of the urinary bladder, longi-
tudinal sections of peripheral nerve were circumscribed by a3182pleomorphic population of round-to-polygonal epithelial cells
with anisocytosis, anisokaryosis, and multiple mitotic ﬁgures,
interpreted as prostatic carcinoma with perineural invasion
(PNI) and extraprostatic extension (Figure 4B).
PIA-Like Lesions Are Present in Areas of Inﬂammation
and Fibrosis
In addition, 1 of 8Ptenþ/mice at 8months and 1 of 10Ptenþ/
mice at 12 months contained regions of the lateral lobe of the
prostate in which multiple prostate glands were lined by ﬂat-
tened, atrophic epithelial cells (Figure 5A). Glands lined by
atrophic epithelium were surrounded by extensive interstitial
ﬁbrosis and inﬂammation. Some affected glands were ectatic.
Interestingly, some glands contained mPIN-like lesions or, in
one instance, a microinvasive carcinoma lesion, despite theirajp.amjpathol.org - The American Journal of Pathology
Figure 3 Experimentally induced prostatitis did not result in increased numbers or severity of epithelial lesions. A: Examples of epithelial lesions in
P3þPtenþ/ and P3Ptenþ/ mice 30 weeks of age (4 months after induction of prostatitis), 46 weeks of age (8 months after induction), and 60 weeks of age
(12 months after induction). The photomicrographs taken from H&E-stained sections represent lesions considered PIN I in the lateral lobe (in both genotypes
at 30 weeks, indicated with arrows; adjacent PIN II lesion indicated with asterisk), PIN III in the dorsal lobe (in both genotypes at 46 weeks), and PIN III
with adjacent foci of invasion in the lateral lobe (both genotypes at 60 weeks). Foci of carcinoma are indicated with arrows in 60 weeks column. Inset at 60
weeks shows p-Akt IHC, showing epithelial cells invading surrounding stroma. B: Total lesion number did not differ between P3þPtenþ/ and P3Ptenþ/ mice
at 4, 8, and 12 months after induction of inﬂammation. Lesions from all four prostate lobes in each mouse were tallied and combined. C: Average lesion grade
for all prostate lobes was obtained for each mouse. Mice with induction of prostatitis have decreased average lesion grade at 4 months after induction
compared with mice without induction of inﬂammation. Both groups had similar lesion grades at 8 and 12 months after induction. D: Size of PIN I lesions in
the dorsal lobe of the prostate did not differ between P3þPtenþ/ and P3Ptenþ/ mice at 4, 8, and 12 months. Size of other lesion types in the other
prostate lobes showed similar results. E: Percentage of mice with each of the mPIN lesion grades and carcinoma was similar at 12 months after induction of
prostatitis (60 weeks), with more P3þPtenþ/ showing carcinoma. Data are expressed as means  SEM (B and C); error bars represent SEM (D). n Z 4 to 5
mice each group (BeD); n Z 5 mice each group (E). *P < 0.05. Mann-Whitney test. IHC, immunohistochemistry.
Lesion Development in POET3þ Ptenþ/ Micequiescent morphologic appearance (Figure 5A). Given the
morphologic similarity of these lesions to the previously
described proliferative inﬂammatory atrophy (PIA) lesions
observed in human prostates, further characterization of theThe American Journal of Pathology - ajp.amjpathol.orgnature of these lesions was initiated.29,30 PIA lesions in men
have been shown to have increased proliferative capacity and
labeling of antiapoptotic proteins, such as Bcl-2.29 Immuno-
histochemical labeling for Ki-67, Bcl-2, and p-Akt was3183
Figure 5 PIA-like lesions developed in two Ptenþ/ mice, one at 8
months and one at 12 months after induction of inﬂammation. A: Photo-
micrographs of H&E-stained sections of lateral prostate from a P3þPtenþ/
mouse (left column). Epithelium lining dilated glands shows features of
PIA, with ﬂattened, low cuboidal cells that contain scant cytoplasm. In the
top panels, epithelial cells show the early stages of microinvasion, dis-
secting through the basement membrane and underlying layers of collagen.
H&E, top right; antiep-Akt, top left. Stretches of affected epithelium have
a high proliferation rate, with increased cells positive for antieKi-67
(bottom right panel). B: PIA-like lesions show higher proliferative rates
than normal epithelium and various amounts of precancerous epithelium
lesions from mice 12 months after induction of inﬂammation. Multiple
lesions were sampled for each category in each mouse. Data are expressed
as means  SEM (B). n Z 10 mice in WNL and PIN groups (B); n Z 1
mouse in carcinoma group (B); nZ 2 mice in PIA group (B). WNL, normal
epithelium.
Figure 4 PNI of prostate carcinoma occurred in a single P3þPtenþ/
mouse approximately 10 months after induction of inﬂammation. A: Gross
image demonstrates hemorrhagic cystitis (asterisk) and prostatomegaly
with hemorrhage (arrows) in a P3þPtenþ/ mouse. B: Photomicrograph of
a H&E-stained section of prostate and adjacent urinary bladder wall shows a
peripheral nerve (asterisk) surrounded by a monomorphic population of
carcinomatous epithelial cells (arrows) exhibiting nuclear pleomorphism,
anisokaryosis, anisocytosis, and increased mitotic rate. Scale bar Z 1 cm.
Burcham et alperformed on sections of prostate containing the PIA-like le-
sions (data not shown and Figure 5A). Although Bcl-2 was not
expressed in these lesions, the proliferative index of affected
epithelium was found to be approximately seven times higher
than normal epithelium, was higher than all grades of mPIN,
and was equally as high as instances of carcinoma (Figure 5B).
Individual glands in other lobes of prostates from P3þPtenþ/
and P3Ptenþ/ mice in the 8- and 12-month time points had
focal areas of atrophied epithelium but were differentiated from
the aforementioned lesions by decreased proliferative indices
and lack of surrounding interstitial ﬁbrosis and inﬂammation.
Experimentally Induced Prostatitis Leads to Increased
Numbers of Lymphoid Cells in Early Time Points;
Spontaneous Prostatitis Tends to Include Increased
Numbers of Myeloid Cells
To better understand the type and severity of prostatitis occur-
ring at these different time points, prostate homogenates were3184analyzed viaﬂow cytometrywith the use of phenotypicmarkers
of leukocyte subsets. Four months after induction of prostatitis,
P3þPtenþ/ mice had a trend toward increased percentage of
CD45þ cells in the prostate (PZ 0.06), with the percentage of
CD45þ cells becoming more even between the two groups at 8
and 12 months after inﬂammation, with the exception of a
single outlier in the P3 12-month group (Figure 6A). The
percentage of lymphoid subsets inﬁltrating prostates at 4
months after induction of inﬂammation was increased for
CD8þ T cells in mice that were previously inﬂamed
(P Z 0.055); when correcting for the percentage of CD45
inﬁltration in each mouse, trends toward increased numbers ofajp.amjpathol.org - The American Journal of Pathology
Figure 6 Lesion development was positively correlated with myeloid cell inﬁltration. A: Percentage of total CD45þ events was measured in prostate ho-
mogenates of P3þPtenþ/ and P3Ptenþ/mice at various time points via ﬂow cytometry. B: CD45þ events were further classiﬁed according to various subsets of
lymphoid cells. Data are displayed as number of cells bearing the indicated antigens per amount of CD45þ cells. At 4 months after induction of prostatitis (30
weeks), P3þPtenþ/mice showed a trend toward greater numbers of lymphoid cells, with signiﬁcantly more CD4þ cells. C:Myeloid subsets were also investigated;
data are displayed as number of cells bearing the indicated antigens per amount of CD45þ cells. P3þPtenþ/ and P3Ptenþ/mice showed increases in all myeloid
subsets over time, with signiﬁcantly more Gr1þ and Gr1þCD11bþ cells at 12 months after induction of prostatitis. B and C: The ﬁrst two bars in each subset
represent the 30-week timepoint, while the last two bars in each subset represent the 60-week timepoint. D: Histologically determined inﬂammation score was
positively correlated with lesion development in a combined cohort of P3þPtenþ/ and P3Ptenþ/ mice at all time points. PZ 0.0035, R2Z 0.2932, linear
regression analysis. E: Lesion development was positively correlated with the percentage of total leukocytes (CD45þ cells) bearing the myeloid markers CD11b and
Gr-1. PZ 0.0002, R2Z 0.4635, linear regression analysis. F: Lesion development was negatively correlated with the percentage of total leukocytes (CD45þ cells)
bearing CD4, CD8, or B220. PZ 0.0168, R2Z 0.2158, linear regression analysis. Data are expressed as means SEM (AeC). nZ 4 to 5 mice each group (AeC).
*P < 0.05, **P < 0.01, and ****P < 0.0001, Student’s t-test.
Lesion Development in POET3þ Ptenþ/ MiceCD8þ, CD4þ, and B220þ cells in P3þ mice were observed,
with signiﬁcantly increased numbers of CD4þ cells (PZ 0.03)
in previously inﬂamed mice (Supplemental Figure S2A and
Figure 6B). The percentage of Gr1þCD11b cells was signif-
icantly increased in P3Ptenþ/ mouse prostates compared
with P3þ mice (P Z 0.028), with trends toward increased
CD11bþGr1 and CD11bþGr1þ cells in P3 mice as well at
the 4-month time point (Supplemental Figure S2B). Taken
together, these results suggest that mice with repeated episodes
of inﬂammation have an inﬁltrate biased toward lymphoid cells,
whereas the P3 mice with spontaneous prostatitis had rela-
tively greater percentages of myeloid cell inﬁltration. At both 8
and 12 months after induction of prostatitis, no statistically
signiﬁcant differences between percentages or numbers of
inﬁltrating leukocytes existed between the P3þ and P3 groups,
suggesting that inﬂammation had normalized between both
groups (Supplemental Figure S2, C and D, and Figure 6, B and
C). However, total numbers of myeloid cells, speciﬁcally
Gr1þCD11bþ cells, increased over time in both groups
(Figure 6C and Supplemental Figure S2D).
Lesion Development across Both P3þPtenþ/ and
P3Ptenþ/ Mice Is Positively Correlated with
Inﬁltration of Myeloid Cells
Although the development of PNI may be associated with
previous episodes of experimentally induced prostatitis, theThe American Journal of Pathology - ajp.amjpathol.orgdevelopment of lesions, including PIN III, PIA, and carcinoma,
occurred in both P3þPtenþ/ and P3Ptenþ/ mice. As pre-
viously reported, we observed the development of prostatitis
and interstitial ﬁbrosis in close proximity to many of these le-
sions.21 We documented a steady increase in the percentage of
total CD45þ cells recovered from whole prostate homogenates
in both groups of mice, indicating that spontaneous prostatitis
occurs in Ptenþ/ mice even without previous episodes of
induced prostatitis (Figure 6A). Given the lack of association of
lesion incidence or grade with induction of inﬂammation, we
hypothesized that the severity of lesions was linked to the
presence of inﬂammation generally, not just the CD8-driven
inﬂammation induced in mice with the POET-3 transgene.
Thus, mice were analyzed post hoc as a single cohort without
regard to the presence or absence of POET-3, via simple linear
regression. In this study, both lesion incidence and lesion grade
were positively correlated with inﬂammation, whether
measured by ﬂow cytometry and the presence of CD45 or by
histologic grade as inﬂammation score (P Z 0.0035,
R2Z 0.2932; data not shown) (Figure 6D). Asmentioned in the
previous subsection, changes in the cellular composition of
prostatitis occurred over time, with P3þPtenþ/mice gradually
moving from a more lymphocyte-based prostatitis to inﬂam-
mation that includes some lymphocytes and various myeloid
subsets. Literature linking inﬂammation and cancer supports the
idea that myeloid-based inﬂammation, which includes macro-
phages and neutrophils, may be the more detrimental type of3185
Figure 7 Inﬂammation in this model lead to decreased IkB protein
expression and IL-6 mRNA expression in prostate epithelial cells. A:
Western blot analyses showed decreased IkB protein in young mice with
OT-Ieinduced inﬂammation and in chronically inﬂamed older mice. Phos-
phorylated IkB concentrations were increased in young mice with
OT-Ieinduced inﬂammation. B: IL-6 mRNA expression was increased in
prostate epithelial cells from young mice with OT-Ieinduced inﬂammation.
Data represented a pooled sample of sorted epithelial cells from two mice in
each group.
Burcham et alinﬂammation in reference to promotion of carcinogenesis.31,32
When a model was ﬁt by using myeloid cell inﬁltration (any
cell with the presence of CD11b, Gr1, or both), lesion incidence
was positively correlated (PZ 0.0015, R2Z 0.3604) with the
percentage of myeloid cell inﬁltrate in the prostate (Figure 6E).
The best ﬁt (PZ 0.0002, R2Z 0.4635) was obtained if only
those myeloid cells bearing both CD11b and Gr1 were used
(data not shown). Conversely, when considering lymphoid
inﬁltrate (any cell bearing CD8, CD4, or B220), lesion inci-
dence was negatively correlated (P Z 0.0168, R2 Z 0.2158)
(Figure 6F). Considering previous data indicating lower lesion
grade and higher numbers of CD4þ lymphocytes in the early 4-
month postinﬂammation group, these results suggested high-
grade epithelial lesions in the prostate may be associated with
the presence of myeloid cell inﬁltrate.
Cytokine expression was also considered in the context
of inﬂamed versus less-inﬂamed mice, as measured via
histopathologic grading; this analysis was done with a
combined cohort including mice with induced and non-
induced inﬂammation. Although no statistically signiﬁcant
differences were observed between P3þPtenþ/ and
P3Ptenþ/ mice for cytokine expression at the 4-, 8-, and
12-month time points, mice with histologically more severe
inﬂammation (those mice with an inﬂammation score of 4 or
higher) had a trend toward increased IL-6 expression
compared with those mice with less inﬂammation and fewer
lesions (Supplemental Figure S3A). Cytokines that char-
acterized the type 1 or acute inﬂammatory response had
similar expression between inﬂamed and less-inﬂamed
mice, and amounts of cytokines that typically associated
with type 2 inﬂammation were typically lower in inﬂamed
mice compared with less-inﬂamed mice at the 12-month
time point (Supplemental Figure S3B). The IL-6 receptor
subunit a did not follow the trend of IL-6, with similar
mRNA expression between inﬂamed and less-inﬂamed
mice at 12 months of age (data not shown). Thus, as pre-
viously reported in other studies of cytokines and prostate
carcinogenesis, IL-6 may play a role in the development of
prostate cancer.
Acute and Chronic Inﬂammation in the Prostates of
P3þPtenþ/ Mice Leads to Decreased IkB
Given that p-Akt has been linked to activation of the tran-
scription factor NF-kB in a PTEN-null prostate cancer-
derived epithelial cell line and that nuclear localization of
NF-kB has been linked to biochemical recurrence of prostate
cancer and tumor grade in human prostate cancer, investi-
gation into whether NF-kB was activated in the PTEN loss
mouse model of prostate cancer may be important.33e35
Little has been done to link NF-kB activation to cancer
development in mouse models of prostate cancer, although
constitutive NF-kB activity has been shown in the transgenic
adenocarcinoma of the mouse prostate model.36 To address
this question, acute prostate inﬂammation was induced via
OT-I injection in two young (2 to 3 months old) P3þPtenþ/3186mice. Nonleukocytic, nonstromal cells were collected via
ﬂuorescent-activated cell sorting in these inﬂamed mice, and
in two young (2 to 3 months old) P3þPtenþ/ mice given
phosphate-buffered saline (uninﬂamed) and two older (12
months old) P3þPtenþ/ mice that had not been dosed with
OT-I cells. Given previous results in Figures 2 and 6, acute
inﬂammation is present in young P3þPtenþ/ mice dosed
with OT-I cells, chronic inﬂammation is present in older
P3þPtenþ/mice, and no inﬂammation was present in young
phosphate-buffered saline-dosed P3þPtenþ/ mice. Western
blot analysis showed decreased IkB in both inﬂamed young
and chronically inﬂamed older P3þPtenþ/ mice compared
with young noninﬂamed mice, suggesting IkB degradation
and resulting NF-kB nuclear localization (Figure 7A).
Decreased IkB corresponded with increased phosphorylated
IkB in inﬂamed young mice but not in chronically inﬂamed
older mice (Figure 7A). Furthermore, IL6, a downstream
target gene of activated NF-kB, showed a many-fold increase
in mRNA expression in sorted nonleukocytic, nonstromal
prostate cells from young inﬂamed mice compared with
young naive mice (Figure 7B). Taken together, these results
suggested that the transcription factor NF-kB is activated in
prostate epithelium after acute, and perhaps chronic,
inﬂammation in P3þPtenþ/ mice.
Discussion
This study was initiated to address the current discrepancies
about the relation between prostatitis and prostate cancer
development in the biomedical literature and to ﬁll a need
for animal models to address this question. The POET-3
mouse speciﬁcally models T-celledriven prostate autoim-
munity, whereas the C57/Luc/Ptenþ/mouse models a slow
progression to prostate cancer, using the genetic alteration
most commonly found in human prostate cancer.37 Ad-
vantages of this particular model include prostate-speciﬁcajp.amjpathol.org - The American Journal of Pathology
Lesion Development in POET3þ Ptenþ/ Miceinﬂammation and Pten gene deletion, acute episodes of T-
celledriven inﬂammation followed by CP to mimic auto-
immunity, progression of epithelial lesion development that
is similar to human prostate cancer, ability to monitor
prostate size in vivo, and a homogenous genetic background
(C57BL/6).20,21,38
Studies that use rodent models of prostatitis and prostate
cancer development have suggested that inﬂammation pro-
motes development or progression of epithelial lesions in
the prostate. Coupled with additional epidemiologic evi-
dence, these studies informed our hypothesis that prostatitis
will promote the progression of epithelial lesions in this
mouse model.16,17 The results of our study were mixed and
suggest a more complex relation between inﬂammation and
cancer development in the prostate. In the simplest setting,
the P3þPtenþ/þ mouse, early time points after induction of
inﬂammation suggest that induced prostatitis may promote
the development of hyperplastic lesions, because one of
three inﬂamed P3þPtenþ/þ mice at 4 months and one of
four mice at 8 months after induction of prostatitis had
hyperplastic epithelial lesions (Supplemental Figure S1A).
Mice in the uninﬂamed control group did not develop his-
tologically recognizable epithelial lesions until 12 months
after treatment, suggesting that prostatitis might induce
hyperplasia more quickly in normal prostate epithelium.
These results are consistent with a role for inﬂammation in
benign prostatic hyperplasia, as suggested by previous
investigators.39e42
Interpretation of inﬂammation in the P3Ptenþ/ and
P3þPtenþ/ mice was more complicated, because results
differed between early and late time points. In P3þPtenþ/
mice, the week immediately after induction of prostatitis had
highly proliferative prostate epithelium, via both biolumi-
nescence and Ki-67 immunolabeling (Figures 1 and 2).
Although bioluminescence in inﬂamed mice remained
increased above the unchallenged mice for several weeks, the
mice examined at 4 months after induction of prostatitis did
not have increased incidence, size, or grade of mPIN lesions.
(Figure 3) In fact, when comparing the average grade of
epithelial lesions across all prostate lobes between inﬂamed
and uninﬂamed mice, previously inﬂamed mice had a lower
average lesion grade. The explanation of this observation
likely lies in the type of inﬂammation that was induced, and
likely persisted, in the prostates of previously inﬂamed mice.
Flow cytometric analysis showed trends toward higher
numbers of lymphoid subsets (CD8þ, CD4þ, B220þ), with
statistically signiﬁcantly more CD4þ T cells in 4-month
prostates of P3þ mice (Figure 6). Previous characterization
of the POET-3model shows signiﬁcantly enhanced expression
of T helper cells type 1 (Th1) and acute inﬂammatory cyto-
kines such as IL-2, IL-12, and tumor necrosis factor-a.20 These
early episodes of inﬂammation likely inﬂuenced recruitment
of Th1 CD4þ cells, as supported by increased numbers
of CD4þ cells at 4 months after inﬂammation, and may
have biased the prostate microenvironment toward a less
cancer-promoting type 1 inﬂammation. Inﬂammation thatThe American Journal of Pathology - ajp.amjpathol.orgdeveloped spontaneously over this same time frame in
P3Ptenþ/ mice was biased toward myeloid-based inﬂam-
mation, which suggests a more tumor-promoting type 2 in-
ﬂammatory microenvironment. Indeed, when mice from all
time points are analyzed without regard for POET-3 status,
lymphoid-based prostatitis was signiﬁcantly negatively
correlated with lesion development, whereas myeloid-based
inﬂammation was signiﬁcantly positively correlated
(Figure 6). These results together suggest that episodes of Th1-
based prostatitis in the P3þPtenþ/ mouse may be protective
in reference to early mPIN development and may lend support
to recently published evidence showing prostatitis as protec-
tive for development of prostate cancer.8,9 Much of the
literature before these referenced studies relied on physician-
diagnosed cases of prostatitis, of which 90% were likely
cases of CP/CPPS.19 Evidence suggests that approximately
one-third of CP/CPPS cases are characterized by biopsy-
determined prostate inﬂammation, and recent studies suggest
that the presence of histologically deﬁned prostatitis is similar
between men with and without symptoms of CP/CPPS.25,43
Many of the patients in previous studies of prostatitis and
cancer development were likely diagnosed on the basis of
pelvic pain and may have lacked histologic prostatitis, which
makes the recent biopsy-based studies in the United States and
Finland much stronger when considering true leukocytic
inﬁltration and its relation to cancer development.
Considering the later time points in our study, 8 and 12
months after induction of prostatitis, the incidence, size, and
average grade of mPIN lesions was similar across both
groups of mice. However, a trend toward invasion was noted
in P3þPtenþ/ mice, with more mice developing carcinoma.
One of the weaknesses of this study was the lack of statistical
power for rare events, such as carcinoma development,
leading to speculation about whether previous bouts of
prostatitis might have promoted invasion at later points.
Because the C57/Luc/Ptenþ/ phenotype includes the
development of spontaneous inﬂammation over time, we had
the opportunity to also analyze lesion development in light of
development of prostatitis in general, whether it was non-
induced (spontaneous) or induced inﬂammation. In these
analyses, lesion incidence and lesion grade were clearly
correlated with inﬂammation, with the most relevant corre-
lation coming when inﬁltration of myeloid cells bearing both
CD11b and Gr1 was considered. As previously mentioned,
cancer development and progression are associated with
speciﬁc leukocyte subsets and speciﬁc cytokine environ-
ments. Macrophages, neutrophils, and myeloid-derived
suppressor cells (MDSCs) all produce substances that are
considered damaging to host cell membranes and DNA, such
as reactive oxygen and nitrogen species. These components
might be helpful to the host if directed at tumor cells them-
selves, but when considering the early development of ma-
lignancy and the progression from lower grade mPIN lesions
to higher grade precursor lesions and eventually invasive
lesions, the products often associated with myeloid cells
might be considered detrimental and tumor promoting.3187
Burcham et alSpeciﬁcally, leukocytes bearing the CD11bþGr1þ pheno-
type might be considered either activated neutrophils or
MDSCs, both of which are known to produce damaging free
radicals that promote cancer progression.44 In addition,
MDSCs may interfere with antitumor immunity via sup-
pression of cytotoxic T cells directed toward tumor anti-
gens.45 Previous work by our group has shown that cells
sorted from prostates of Pten/ mice have the capacity to
suppress T-cell proliferation.21 We also evaluated Ptenþ/
mice for MDSC-mediated suppression at 7 months of age
and observed strong inhibition of T-cell proliferation (data
not shown). On the basis of these observations, a portion of
the CD11bþGr1þ inﬁltrating cells in this report are consid-
ered MDSCs that may have contributed to lesion
progression.21
In addition to the previous ﬁndings, two interesting and
unique lesions were noted in mice from this study: PNI and
PIA. Although PNI is a common occurrence in prostate
cancer and has been linked to poorer prognosis in other
cancers, the role of PNI in predicting prostate cancer outcome
is not clear.46e48 PNI has been documented in a chemically
induced rat model of prostate cancer, two mouse models
using the SV40-Tag transgene, a single mouse with over-
expression of human 15-lipoxygenase-1, and mice with
double knockout of Pten and TP53, but it has not been
documented in mice with loss of only Pten, to our knowl-
edge.49e53 Lesions resembling PIA have not been described
in mouse models of prostate cancer. A consensus report
relating to interpretation of lesions in transgenic mouse
models have described epithelial atrophy in mice after
castration but it has not related these lesions to previous
episodes of inﬂammation or characterized them according to
their proliferative capacity.22 Interestingly, these lesions
developed in prostates of Ptenþ/ mice that had severe
prostatitis, either from previous induction with OT-I T cells
or spontaneous development. At least one report in rats and
one report in mice both dosed with 2-amino-1-methy-6-
phenylimidazo (4,5-b) pyridine show development of pros-
tatitis, followed by atrophic epithelial lesions, suggesting that
this particular lesion may develop as a result of inﬂammation
and partial destruction of the epithelial lining.54,55 Atrophic
lesions in the treated rats and mice developed after prostatitis
and had some degree of cellular atypia in the rats; however,
proliferative indices of these lesions were not speciﬁcally
assessed.54,55 The morphology of these lesions in Ptenþ/
mice certainly seems to suggest previous injury and cell loss,
as in the rat model, with ﬂattening of epithelial cells to cover
the basement membrane. With only two mice having these
lesions, determination of their cause is speculative. Phos-
phorylation of Akt in the Ptenþ/ microenvironment during
the acute phase of prostatitis (Figure 2C) or during the
development of spontaneous inﬂammation later on likely
leads to phosphorylation of Bad and subsequently allows
Bcl-2 to inhibit epithelial cell apoptosis during severe
inﬂammation in our model, as occurs in animal models of
prostate cancer and prostate cancer cell lines.56,57 Although3188the pathogenesis of PIA in men is unknown, overexpression
of Bcl-2 has been shown in human PIA lesions, suggesting
that previous Akt signaling and/or loss of Pten, accumulation
of Bcl-2, and development of PIA may be linked.
Perhaps a more interesting observation related to these
lesions is that in one instance, epithelial cells arising from a
PIA-like gland dissect through the basement membrane and
underlying layers of collagen to exhibit early microinvasion.
PIA lesions and their spatial and temporal association with
high-grade PIN and prostate adenocarcinoma in men have
been well documented; however, only a single publication
shows a direct morphologic link between atrophic glands and
carcinoma in human prostate tissue, and the lesions are not
currently considered true precursors of adenocarci-
noma.29,30,58,59 The cancer-like properties of the epithelium,
including their increased proliferative capacity and resistance
to apoptosis, at least in men, make them suspect as cancer
precursors. Although the lesions described here differ from
the human lesions in their expression of an antiapoptotic
protein, their highly proliferative nature and morphologic
similarities suggest that they may be analogous entities.
Documented early microinvasion of the basement membrane
suggests that atrophic epithelial lesions with highly prolif-
erative capacity may indeed represent a precursor lesion to
prostate carcinoma.
A ﬁnal part of this study considered expression of cyto-
kines in whole prostate homogenates. Although no statisti-
cally signiﬁcant differences were observed between
P3Ptenþ/ and P3þPtenþ/mice, a trend toward increasing
IL-6 expression in mice with a histologic inﬂammation score
of 4 or greater was observed when mice of all genotypes and
time points were examined. As previously mentioned, IL-6
has been one of the cytokines most indicated in prostate
carcinogenesis, with evidence coming from in vitro studies of
IL-6 and prostate cancer cell lines, increases in IL-6 in sera of
patients at risk of prostate cancer development, and genetic
polymorphisms in the IL-6 and IL-6 receptor genes confer-
ring decreased risk of prostate cancer development.14,60,61
Although the trends we observed were not statistically sig-
niﬁcant, they support previous literature suggesting a role for
IL-6 in prostate carcinogenesis. Interestingly, IL-6 has been
shown to activate the phosphatidylinositol 3-kinase/Akt
pathway and trigger expression of cyclin A1, with positive
effects on survival in prostate cancer cell lines.62 Thus,
chronic inﬂammation may promote Akt pathway activity in
the prostate. Given that loss of Pten, and subsequent
increased Akt activity, without additional inﬂammatory
stimuli (ie, no OT-I injection) leads to prostate inﬂammation
in this model, the fact that IL-6 can lead to further Akt
stimulation could potentially establish a cycle of constant
inﬂammation and Akt stimulation.
To add information about the pathogenesis of inﬂam-
mation and cancer development in this particular model,
additional experiments were undertaken to understand
whether the transcription factor NF-kB was activated
in prostate epithelial cells in these mice. Protein analysisajp.amjpathol.org - The American Journal of Pathology
Lesion Development in POET3þ Ptenþ/ Miceshowed decreased IkB in acutely inﬂamed young P3þ
Ptenþ/ mice and chronically inﬂamed older P3þPtenþ/
mice, suggesting degradation of this protein and subsequent
release of NF-kB to allow nuclear localization in prostate
epithelial cells. Thus, inﬂammation in this model seems to
promote NF-kB activation, which in turn would allow a
positive feed-forward process to further promoting inﬂam-
mation and epithelial cell survival and proliferation.63
Furthermore, IL6, a NF-kB target gene implicated in the
progression of prostate cancer, was also found to be up-
regulated in prostate epithelial cells during episodes of
acute inﬂammation. This ﬁnding further supports that NF-
kB is activated in our model after inﬂammation, but it also
lends some insight into the source of IL-6 in the prostate
microenvironment, because IL-6 was found to be up-
regulated in prostate homogenates with greater inﬂamma-
tion (Figure 6).
Conclusions
Our study suggests that the relation between inﬂammation
and prostate cancer is complex and depends largely on the
type of inﬂammatory microenvironment present in the
prostate and the state of the epithelium (normal or loss of
Pten). Inﬂammation dominated by T cells and type 1 cy-
tokines likely leads to slower progression of epithelial
precursor lesions, even if epithelial proliferation is high
after episodes of inﬂammation. In contrast, inﬂammation
that includes more myeloid cells, especially CD11bþGr1þ
cells, is associated with increased incidence of mPIN and
higher grade epithelial lesions. In addition, previous bouts
of T-celledriven prostatitis or development of spontaneous
inﬂammation may lead to focal damage of epithelium that
later develops into atrophic epithelium with a high rate of
proliferation and the potential for invasion. Finally, IL-6, a
cytokine produced both in acute inﬂammation and by type
2-skewed macrophages and CD4þ T cells, is likely
important for the development of epithelial lesions in the
P3þPtenþ/ prostate. Further studies using this model
would be beneﬁcial to advance our understanding of the
cellular and molecular components of the inﬂammatory
response that are associated with the development and
progression of prostate cancer.
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